The Motley Fool

Forget the FTSE 100! I think these FTSE 250 dividend stocks could help you get rich

It’s mighty tempting for dividend investors to storm right into the FTSE 100 without a second thought.

Aside from the prestige that comes with holding stock in some of Britain’s most distinguished blue-chips, dividends from London’s elite index continue to hit record after record and are predicted to continue doing so for some time yet.

Claim your FREE copy of The Motley Fool’s Bear Market Survival Guide.

Global stock markets may be reeling from the coronavirus, but you don’t have to face this down market alone. Help yourself to a FREE copy of The Motley Fool’s Bear Market Survival Guide and discover the five steps you can take right now to try and bolster your portfolio… including how you can aim to turn today’s market uncertainty to your advantage. Click here to claim your FREE copy now!

It’d be a mistake, though, to limit your shopping basket by not forensically foraging outside the Footsie for other great income stocks. With this in mind I’ve searched the FTSE 250 for some big dividend payers that could deliver some stunning returns in the years ahead. 

In great health

I like Assura (LSE: AGR) a lot. For income chasers it offers that essential quality of reliable earnings growth year after year thanks to its role in the healthcare sector (it designs, builds and manages primary healthcare properties the length and breadth of the country).

It remains committed to growth and thanks to its robust balance sheet the business is able to embark on an aggressive expansion drive. In 2018, Assura splashed out a total £175m to secure 45 new medical centres and develop two further assets, taking the total number of healthcare facilities on its books to a whopping 553 with a total annualised rent roll of £99.8m (versus £87.4m a year earlier).

Encouraged by its expansion drive and the defensive nature of its operations, City brokers expect Assura’s profits to keep growing over the next few years at least, thus keeping the firm’s long-running record of dividend growth up and running. And this means that the healthcare star sports an inflation-smashing yield of 4.6% for this year alone.

Turn the page

If you’re hunting for bigger near-term yields, though, then PageGroup (LSE: PAGE) may well be right up your street.

City analysts are expecting earnings at the recruitment giant to keep rising by double-digit percentages in 2019, laying the groundwork for predictions of more weighty dividend growth and thus a gigantic 6.4% yield.

I’ve long talked up PageGroup’s investment appeal because of its exposure to fast-growing economies around the globe and I was pleased to see that January’s trading update revealed more of the same.

Sure, tough economic conditions in the UK are hampering performance in its home territory and gross profit fell 1.7% in 2018. However, stunning growth elsewhere — PageGroup produced record results in 23 countries in which it operates last year — helped to drive gross profits at group level 14.5% higher. And in its so-called high potential territories of the US, Germany, Latin America, Greater China and South East Asia, profits surged by a collective 25% year-on-year.

Clearly the jobs giant is on the up and up, and with it aiming to boost its global headcount to 10,000 from the all-time high of around 7,800 to capitalise on these fertile markets, there should be plenty more to come.

There’s a ‘double agent’ hiding in the FTSE… we recommend you buy it!

Don’t miss our special stock presentation.

It contains details of a UK-listed company our Motley Fool UK analysts are extremely enthusiastic about.

They think it’s offering an incredible opportunity to grow your wealth over the long term – at its current price – regardless of what happens in the wider market.

That’s why they’re referring to it as the FTSE’s ‘double agent’.

Because they believe it’s working both with the market… And against it.

To find out why we think you should add it to your portfolio today…

Click here to read our presentation.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.